查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2008031

內分泌治療藥物（ETDs）市場：按藥物類型、應用、分銷管道和地區分類

Endocrine Therapy Drugs (ETDs) Market, By Drug Type, By Application, By Distribution Channel, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 151 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2026年內分泌治療藥物（ETD）市場規模估計為353億美元，預計2033年將達到500億美元。預計從2026年到2033年，其複合年成長率將達到5.1%。

報告範圍 報告詳情
基準年： 2025 2026年市場規模： 353億美元
歷史數據時期： 2020年至2024年 預測期： 2026年至2033年
2026年至2033年預測期間的複合年成長率： 5.10% 2033年市場規模預測： 500億美元

人體分泌系統利用荷爾蒙來控制和調節新陳代謝、生殖、能量水平、生長發育以及對壓力、損傷和情緒障礙的反應。內分泌療法，也稱為荷爾蒙療法，包括補充、阻斷或去除荷爾蒙和化學物質，以治療乳癌和糖尿病等疾病。雌激素和黃體素存在於女性體內，它們會促進細胞增生和擴散，進而加重乳癌。目前有兩種乳癌療法用於治療乳癌：一種是抑制雌激素和黃體素的作用以阻止癌細胞生長；另一種是手術切除或其他阻止卵巢產生雌激素和黃體素的手術。用於治療乳癌的內分泌藥物包括阿貝西利（Verzenio）、Anastrozole（Arimidex）、依西美坦（Aromasin）和氟維司群（Faslodex）。

市場動態

預計在預測期內，糖尿病和乳癌等慢性疾病的日益普遍、針對新型內分泌療法 (ETD) 的研發活動的活性化，以及市場主要企業擴大採用收購和合作等非內部成長策略，將成為全球內分泌療法 (ETD) 市場成長的主要驅動力。

例如，根據國際糖尿病聯盟（IDF）發布的《2019年糖尿病地圖集》，截至2019年，全球約有4.63億20至79歲的人患有糖尿病，約有1.36億65歲及以上的老年人患有糖尿病。此外，根據IDF發布的《2019年糖尿病地圖集》，哥斯大黎加的糖尿病盛行率預計將從2019年的9.1%上升到2030年的10.3%。

本次調查的主要特點。

  • 本報告對全球內分泌治療藥物（ETD）市場進行了詳細分析，以 2021 年為基準年，對預測期（2022-2030 年）的市場規模和復合年成長率進行了預測。
  • 本報告指出了各個細分市場的潛在商機，並說明了該市場中具有吸引力的投資提案矩陣。
  • 此外，本研究還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要企業所採取的競爭策略的關鍵見解。
  • 本報告根據以下參數介紹了全球內分泌治療藥物 (ETD) 市場主要企業的概況：公司概況、財務績效、產品系列、市場地位、分銷策略、主要發展、策略和未來計劃。
  • 透過利用本報告中提出的見解，企業行銷負責人和經營團隊可以就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
  • 本報告面向該產業的各類相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
  • 相關人員可以透過利用分析全球內分泌治療 (ETD) 市場中使用的各種策略矩陣來簡化決策過程。

目錄

第1章：研究目標與前提條件

  • 研究目標
  • 前提
  • 簡稱

第2章 市場範圍

  • 報告摘要
    • 市場定義和範圍
  • 執行摘要
  • Coherent Opportunity Map（COM）

第3章：市場動態、監管與趨勢分析

  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機遇
  • 影響分析
  • 管道分析
  • PEST分析
  • 法規環境
  • 市場趨勢
  • 主要亮點
  • 救贖方案
  • 併購
  • 流行病學

第4章 全球內分泌治療藥物（ETD）市場：依藥物類型分類，2026-2033年

  • 抗糖尿病藥物
  • 抗骨質疏鬆藥物
  • 避孕藥
  • 乳癌治療藥物
  • 其他（例如，治療更年期症狀的藥物）

第5章 全球內分泌治療藥物（ETD）市場：依應用領域分類，2026-2033年

  • 糖尿病
  • 乳癌
  • 骨質疏鬆症
  • 停經
  • 避孕
  • 其他（變性手術、甲狀腺機能低下症等）

第6章 全球內分泌治療藥物（ETD）市場：依通路分類，2026-2033年

  • 醫院藥房
  • 零售藥房
  • 網路藥房

第7章 全球內分泌治療藥物（ETD）市場：依地區分類，2026-2033年

  • 北美洲
    • 美國
    • 加拿大
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 其他拉丁美洲
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 韓國
    • ASEAN
    • 亞太其他地區
  • 中東
    • GCC
    • 以色列
    • 其他中東國家
  • 非洲
    • 南非
    • 中非
    • 北非

第8章 競爭情勢

  • 熱圖分析
  • 市佔率分析
    • Novo Nordisk A/S
    • AstraZeneca
    • Generex Biotechnology
    • Orion Pharma AB
    • Sanofi
    • Teva Pharmaceutical Industries Ltd.
    • F. Hoffmann-La Roche
    • Hisamitsu Pharmaceutical Co.,Inc.
    • Bayer AG
    • Eli Lilly and Company
    • Abbott
    • Tonghua Dongbao Pharmaceutical Co., Ltd.
    • Merck &Co., Inc.
    • TherapeuticsMD, Inc.
    • Pfizer Inc.
    • Allergan
    • BioSante Pharmaceuticals
    • Amgen Inc.
    • Noven Pharmaceuticals, Inc.
    • QuatRx Pharmaceuticals

第9章

  • 參考
  • 調查方法
簡介目錄
Product Code: CMI5193

Endocrine Therapy Drugs (ETDs) Market is estimated to be valued at USD 35,300 Mn in 2026 and is expected to reach USD 50,000 Mn by 2033, growing at a compound annual growth rate (CAGR) of 5.1 % from 2026 to 2033.

Report Coverage Report Details
Base Year: 2025 Market Size in 2026: USD 35,300 Mn
Historical Data for: 2020 To 2024 Forecast Period: 2026 To 2033
Forecast Period 2026 to 2033 CAGR: 5.10% 2033 Value Projection: USD 50,000 Mn

The endocrine system of the human body uses hormones to control and coordinate with the human body's metabolism, reproduction, energy level, growth and development, as well as response for stress, injury, and mood disorders. Endocrine therapy, also known as hormone therapy, adds, blocks, or removes hormones/chemicals in order to treat diseases such as breast cancer, diabetes, etc. Estrogen and progesterone found in a woman's body can aggravate breast cancer as these hormones help the cells grow and spread throughout the body. Two types of endocrine therapy can be used for the treatment of breast cancer: blocking the action of estrogen and progesterone to stop them from helping cancerous cells to grow and, ablation or surgery to stop the ovary from producing estrogen and progesterone. Some of the endocrine therapy drugs used in breast cancer treatment include Abemaciclib (Verzenio), Anastrozole (Arimidex), Exemestane (Aromasin), and Fulvestrant (Faslodex), among others

Market Dynamics

The increasing prevalence of chronic diseases such as diabetes, breast cancer, and others, rising research and development activities to develop novel endocrine therapy drugs (ETDs), and increasing adoption of inorganic growth strategies such as acquisitions and collaborations by key players operating in the market are the major factors that are expected to drive growth of the global endocrine therapy drugs (ETDs) market over the forecast period.

For instance, according to the International Federation of Diabetes Atlas 2019, around 463 million people aged 20-79 years and 136 million people aged 65 are estimated to be suffering from diabetes in 2019, globally. Moreover, according to the International Diabetes Federation Diabetes Atlas 2019, the prevalence of diabetes in Costa Rica is predicted to increase form 9.1 in 2019 to 10.3 by 2030.

Key features of the study

  • This report provides an in-depth analysis of the global endocrine therapy drugs (ETDs) market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global endocrine therapy drugs (ETDs) market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Novo Nordisk A/S, AstraZeneca, Generex Biotechnology, Orion Pharma AB, Sanofi, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche, Hisamitsu Pharmaceutical Co.,Inc., Bayer AG, Eli Lilly and Company, Abbott, Tonghua Dongbao Pharmaceutical Co., Ltd., Merck & Co., Inc., TherapeuticsMD, Inc., Pfizer Inc., Allergan, BioSante Pharmaceuticals, Amgen Inc., Noven Pharmaceuticals, Inc., and QuatRx Pharmaceuticals
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global endocrine therapy drugs (ETDs) market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global endocrine therapy drugs (ETDs) market

Market Segmentation

  • By Drug Type
    • Anti-diabetic Drugs
    • Anti-osteoporosis Drugs
    • Contraceptive Drugs
    • Breast Cancer Drugs
    • Others (Menopause Drugs, among others)
  • By Application
    • Diabetes
    • Breast Cancer
    • Osteoporosis
    • Menopause
    • Contraception
    • Others (Gender Reassignment Surgery, Hypothyroidism, among others)
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
    • South Africa
    • North Africa
    • Central Africa
  • Key Players
    • Novo Nordisk A/S
    • AstraZeneca
    • Generex Biotechnology
    • Orion Pharma AB
    • Sanofi
    • Teva Pharmaceutical Industries Ltd.
    • Hoffmann-La Roche
    • Hisamitsu Pharmaceutical Co.,Inc.
    • Bayer AG
    • Eli Lilly and Company
    • Abbott
    • Tonghua Dongbao Pharmaceutical Co., Ltd.
    • Merck & Co., Inc.
    • TherapeuticsMD, Inc.
    • Pfizer Inc.
    • Allergan
    • BioSante Pharmaceuticals
    • Amgen Inc.
    • Noven Pharmaceuticals, Inc.
    • QuatRx Pharmaceuticals

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Type
    • Market Snippet, By Application
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Pipeline Analysis
  • PEST Analysis
  • Regulatory Scenario
  • Market Trends
  • Key Highlights
  • Reimbursement Scenario
  • Mergers & Acquisitions
  • Epidemiology

4. Global Endocrine Therapy Drugs (ETDs) Market, By Drug Type, 2026 - 2033, (USD Mn)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2026 - 2033
    • Segment Trends
  • Anti-diabetic Drugs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
  • Anti-osteoporosis Drugs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
  • Contraceptive Drugs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
  • Breast Cancer Drugs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
  • Others (Menopause Drugs, among others)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)

5. Global Endocrine Therapy Drugs (ETDs) Market, By Application, 2026 - 2033, (USD Mn)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2026 - 2033
    • Segment Trends
  • Diabetes
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
  • Breast Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
  • Osteoporosis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
  • Menopause
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
  • Contraception
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
  • Others (Gender Reassignment Surgery, Hypothyroidism, among others)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)

6. Global Endocrine Therapy Drugs (ETDs) Market, By Distribution Channel, 2026 - 2033, (USD Mn)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2026 - 2033
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)

7. Global Endocrine Therapy Drugs (ETDs) Market, By Region, 2026 - 2033, (USD Mn)

  • Introduction
    • Market Share Analysis, By Region, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, For Regions, 2026-2033
  • North America
    • Market Size and Forecast, By Drug Type, 2026 - 2033, (USD Mn)
    • Market Size and Forecast, By Application, 2026 - 2033, (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2026 - 2033, (USD Mn)
    • Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
      • U.S.
      • Canada
  • Latin America
    • Market Size and Forecast, By Drug Type, 2026 - 2033, (USD Mn)
    • Market Size and Forecast, By Application, 2026 - 2033, (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2026 - 2033, (USD Mn)
    • Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • Market Size and Forecast, By Drug Type, 2026 - 2033, (USD Mn)
    • Market Size and Forecast, By Application, 2026 - 2033, (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2026 - 2033, (USD Mn)
    • Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Type, 2026 - 2033, (USD Mn)
    • Market Size and Forecast, By Application, 2026 - 2033, (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2026 - 2033, (USD Mn)
    • Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • Market Size and Forecast, By Drug Type, 2026 - 2033, (USD Mn)
    • Market Size and Forecast, By Application, 2026 - 2033, (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2026 - 2033, (USD Mn)
    • Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Drug Type, 2026 - 2033, (USD Mn)
    • Market Size and Forecast, By Application, 2026 - 2033, (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2026 - 2033, (USD Mn)
    • Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
      • South Africa
      • Central Africa
      • North Africa

8. Competitive Landscape

  • Heat Map Analysis
  • Market Share Analysis
    • Novo Nordisk A/S
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • AstraZeneca
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Generex Biotechnology
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Orion Pharma AB
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Sanofi
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Teva Pharmaceutical Industries Ltd.
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • F. Hoffmann-La Roche
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Hisamitsu Pharmaceutical Co.,Inc.
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Bayer AG
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Eli Lilly and Company
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Abbott
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Tonghua Dongbao Pharmaceutical Co., Ltd.
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Merck & Co., Inc.
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • TherapeuticsMD, Inc.
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Pfizer Inc.
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Allergan
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • BioSante Pharmaceuticals
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Amgen Inc.
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Noven Pharmaceuticals, Inc.
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • QuatRx Pharmaceuticals
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
      • Analyst Views

9. Section

  • References
  • Research Methodology
  • About us and Sales Contact